| P/E (FY) | 53.2 | Sales (TTM) | $72.25B |
| Earnings (TTM) | $25.28B | ROE | 101.16% |
| Net Margin | 31.67% | ROIC | — |
| Debt / Equity | 1.60 | TD / EBITDA | — |
| EPS Growth 3Y | 49.27% | Sales Growth 3Y | 31.69% |
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in a single business segment. Its cardiometabolic portfolio includes Mounjaro and Zepbound (GIP/GLP-1 receptor agonists), Jardiance, and multiple insulin products. Its oncology portfolio includes Cyramza, Erbitux, and Inluriyo, among others. Products are sold in approximately 90 countries. Manufacturing and distribution facilities are located in the United States (including Puerto Rico), Europe, and Asia. The company's long-term strategy centers on the continual discovery, acquisition, and commercialization of innovative medicines. Lilly was incorporated in 1901, succeeding a drug manufacturing business originally founded in Indianapolis in 1876.
| Market Cap | $1.15T | Trading Days | 3781 |
| 52W High | 1249.45 |
| 52W Low | 623.78 |
| % Off High | −2.30% |
| YTD | 13.97% | 1Y | 52.12% |
| 3Y | 171.98% | 5Y | 419.10% |
| 10Y | 1629.78% | Since incept. (ann.) | 29.01% |
Reportable 100%
| Ann. Volatility (1Y) | 38.75% | Ann. Volatility (3Y) | 36.15% |
| Sharpe (1Y) | 1.29 | Sharpe (3Y) | 1.12 |
| Max Drawdown (1Y) | −23.18% | Max Drawdown (3Y) | −34.48% |
| Beta (3Y, vs SPY) | 0.38 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | $640.91B | 24.1 |
| ONC | BeOne Medicines Ltd. | $471.01B | 1715.3 |
| ABBV | AbbVie Inc. | $453.91B | 108.9 |
| MRK | Merck & Co., Inc. | $322.95B | 18.0 |
| ABT | ABBOTT LABORATORIES | $182.00B | 28.1 |
| PFE | PFIZER INC | $140.61B | 18.1 |
| BMY | BRISTOL MYERS SQUIBB CO | $127.75B | 18.1 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $121.57B | 31.3 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $62.68B | 16.1 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $36.92B | 119.5 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.19B | 25.7 |
| RPRX | Royalty Pharma plc | $33.15B | 33.0 |
